Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An update from SAB Biotherapeutics ( (SABS) ) is now available.
On April 22, 2026, SAB BIO presented new clinical and mechanistic data from its Phase 1 HUMAN trial of SAB-142 in adults with established Stage 3 type 1 diabetes at the Immunology of Diabetes Society Congress in Brisbane. All four patients treated with SAB-142 showed preservation of C-peptide, three met a super responder profile linked to CD4+ T conventional cell exhaustion, and they achieved improved glycemic control without higher insulin use versus a placebo patient who followed expected disease decline.
The data suggest SAB-142 can induce sustained immunomodulation without immunodepletion, supporting its differentiation as a potentially safer long-term immunotherapy relative to rabbit anti-thymocyte globulin. These Phase 1 findings bolster the company’s confidence in SAB-142’s disease‑modifying potential and underpin ongoing global enrollment in the Phase 2b SAFEGUARD trial in newly diagnosed Stage 3 type 1 diabetes patients.
The most recent analyst rating on (SABS) stock is a Buy with a $13.00 price target. To see the full list of analyst forecasts on SAB Biotherapeutics stock, see the SABS Stock Forecast page.
Spark’s Take on SABS Stock
According to Spark, TipRanks’ AI Analyst, SABS is a Neutral.
The score is held back primarily by weak financial performance (revenue collapse, sustained operating losses, and ongoing cash burn). Corporate updates and financing improve runway and support pipeline progress, while technicals are only modest and valuation appears low on P/E but lacks dividend support and is tempered by fundamental risk.
To see Spark’s full report on SABS stock, click here.
More about SAB Biotherapeutics
SAB Biotherapeutics, Inc. (SAB BIO) is a clinical-stage biopharmaceutical company developing multi-specific, high-potency fully human immunoglobulin G therapies for immune and autoimmune disorders. Using genetically engineered transchromosomic cattle to produce human antibodies, its lead candidate SAB-142 targets autoimmune type 1 diabetes as a disease-modifying treatment now in a registrational Phase 2b trial.
Average Trading Volume: 557,258
Technical Sentiment Signal: Buy
Current Market Cap: $196.7M
For a thorough assessment of SABS stock, go to TipRanks’ Stock Analysis page.